Hybrigenics today announced the positive outcomes of clinical tolerance Phase IIa study of daily oral inecalcitol in combination with gold standard Taxotere chemotherapy in hormone-refractory prostate cancer patients.
The maximal tolerated dose of inecalcitol is 4 milligrams (mg) per day and the response rate to combination treatment reached 85 per cent based on Prostate-Specific Antigen (PSA) decline within 3 months.
Showing posts with label Taxotere. Show all posts
Showing posts with label Taxotere. Show all posts
Subscribe to:
Posts (Atom)